Kerala Ayurveda Share Price

Kerala Ayurveda Limited, with its corporate operations in Aluva, functions as an ayurvedic products and healthcare services company in India. The company was founded in 1945 and has evolved into an integrated ayurvedic healthcare provider . Kerala Ayurveda manufactures classical and proprietary ayurvedic medicines, including therapeutic formulations, as well as health supplements, skin and beauty care products, and specialty foods. The company also provides wellness centers and clinics, hospitals, health villages, wellness resorts, yoga therapy services, and operates ayurvedic academies. Kerala Ayurveda manages the cultivation of ayurvedic herbs and maintains a herbarium of medicinal plants.

Kerala Ayurveda share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical and wellness sector. The company’s financial health depends on product sales volumes, raw material costs including medicinal herbs and botanical extracts, domestic demand from retail and institutional customers, and the performance of its ayurvedic medicine and healthcare services segments. Kerala Ayurveda stock price is influenced by various factors such as earnings, regulatory changes in the pharmaceutical industry including AYUSH standards, consumer wellness trends, and competition from herbal and nutraceutical players. In the longer run, strategies such as expansion of wellness centers, new product development, and strengthening of distribution networks affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Kerala Ayurveda live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Kerala Ayurveda live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Kerala Ayurveda stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Kerala Ayurveda Limited Company Fundamentals

a. Company Background

Kerala Ayurveda Limited was founded in 1945 and is headquartered in Aluva, India. The company is a wholly-owned subsidiary of Katra Holdings Limited. Kerala Ayurveda emerged from the merger of Kerala Pharmacy and Pensen Drugs and Pharmaceuticals in 1992, drawing on the rich experience of its parent companies. The company came out with a public issue in February 1995 to part-finance its expansion and diversification programme. Kerala Ayurveda is engaged in the manufacturing and selling of ayurvedic products and also provides healthcare services. Its operations include the cultivation of ayurvedic herbs and maintaining a herbarium of medicinal plants. The company operates wellness centers, clinics, hospitals, a health village, and yoga therapy services, as well as academies for ayurvedic education. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical sector. Overall fundamentals are influenced by raw material availability, demand cycles in healthcare, and input cost fluctuations.

b. Company Product Lines

• Ayurvedic medicines: Classical and proprietary therapeutic formulations for various health conditions including pain relief, joint and muscle care, women and men health, immunity and general wellness, stress management and brain health.

• Health supplements: Nutritional and dietary supplements for daily wellness and specific health needs including metabolism and gut health, child care and teen health, and geriatric care.

• Skin and beauty care products: Ayurvedic formulations for skin health, hair care, and personal care.

• Specialty foods: Ayurvedic food products and nutraceuticals for targeted health benefits.

• Healthcare services: Wellness centers, clinics, hospitals, health village, wellness resort, and yoga therapy services.

• Educational services: Ayurvedic academies offering training and education in ayurvedic medicine and practices.

• The company also engages in the cultivation of ayurvedic herbs and maintains a herbarium of medicinal plants

c. Company Revenue Model

• Domestic sales of ayurvedic medicines, health supplements, and beauty products to distributors, hospitals, retail pharmacies, and consumers across India

• Revenue from healthcare services including wellness centers, clinics, hospitals, and yoga therapy services

• Income from ayurvedic academies and educational programs

• Institutional and bulk contracts with healthcare institutions and corporate wellness programmes

• Revenue performance is primarily influenced by demand for ayurvedic products and services, raw material costs (especially medicinal herbs), and selling price realizations in domestic markets, along with the growth of wellness tourism and preventive healthcare trends

d. Geographic Presence

• Corporate headquarters located at Athani Post, Ernakulam District, Aluva, Kerala, India

• Manufacturing facilities located in Kerala, India

• Domestic distribution network across India through franchisees and stockists, with established presence in Kerala, Tamil Nadu, Karnataka, Maharashtra, and other states

• Wellness centers, clinics, and hospital facilities located in various regions of India

• The company operates through 75 franchisees and 400 stockists with a well entrenched presence in several states

e. Key Milestones

• 1945: Foundation of the company

• 1992: Merger of Kerala Pharmacy and Pensen Drugs and Pharmaceuticals

• 1995: Public issue to part-finance expansion-cum-diversification programme

• 2006: Listing on Bombay Stock Exchange (BSE) in February

• Recent years: Continued focus on expansion of wellness centers, ayurvedic academies, and healthcare services, along with product portfolio diversification

f. Industry Perspective

The ayurvedic and pharmaceutical industry in India is growing steadily, driven by increasing consumer awareness of natural and holistic healthcare solutions. The industry is capital-intensive and closely linked to demand from healthcare, wellness, and personal care sectors. Demand trends are influenced by economic activity, disposable income levels, preventive healthcare awareness, and the growth of the nutraceutical and herbal supplements market. The industry is also affected by fluctuations in raw material prices of medicinal herbs, botanical extracts, and other natural ingredients, along with energy and logistics costs. Regulatory frameworks such as AYUSH standards and good manufacturing practices compliance requirements are increasingly shaping production practices and capital investment decisions. Companies in the sector must manage competitive pressures, regulatory approvals, and supply chain complexities while maintaining operational efficiency and product quality. These factors collectively influence financial performance and investor perception of firms like Kerala Ayurveda.

Kerala Ayurveda Limited Stock Market Presence: Listings & Index Representation

Kerala Ayurveda Limited is listed on the Bombay Stock Exchange (BSE) with the scrip code 530163. Kerala Ayurveda share price is actively traded on the BSE platform. The company’s shares were listed on the BSE in February 2006. Kerala Ayurveda is also listed on certain other regional exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Kerala Ayurveda stock price is generally tracked by investors interested in the ayurvedic pharmaceutical and wellness industry.

Kerala Ayurveda Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices that track small-cap and pharmaceutical sector companies. Kerala Ayurveda share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical and ayurvedic companies.

Kerala Ayurveda Limited Stock Performance and Share Price History

Kerala Ayurveda share price on BSE reflects its status as an ayurvedic pharmaceutical and healthcare services provider in India. Performance is driven by product sales volumes, healthcare service demand, raw material cost management, and the company’s ability to manage operational expenses. Investors compare Kerala Ayurveda share price today with other pharmaceutical and wellness companies to gauge relative performance.

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Kerala Ayurveda share price. In addition to operational and sector-led factors, corporate actions such as the company’s public issue and listing on the BSE have shaped the company’s capital structure over the long term. This shows how corporate actions can have lasting impacts on the company’s financial positioning, even within a regulated pharmaceutical framework influenced by healthcare policies and wellness trends.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Kerala Ayurveda share price 52-week high and low, providing context beyond daily or weekly changes. Based on available data, the stock’s 52-week high stood at approximately 625.00, while the 52-week low stood at approximately 150.00. Highs suggest stronger ayurvedic product demand and positive market sentiment, while lows align with market corrections or sector volatility. These levels capture impacts of pharmaceutical policies, healthcare trends, and earnings visibility, providing context for the stock’s historical performance.

Kerala Ayurveda’s stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s ayurvedic healthcare ecosystem. The company’s diversified portfolio across ayurvedic medicines, wellness services, and educational programs has shaped its Kerala Ayurveda share price history. Over the past five years, the stock has shown periods of sharp gains and phases of consolidation. The stock delivered a positive five-year return of approximately 328.12 percent, a positive three-year return of approximately 155.9 percent, while recording a negative one-year return of approximately 31.39 percent. The stock has shown significant volatility, with a beta of approximately 0.65 over one year, 0.96 over three years, and 0.35 over one month. From recent periods onwards, the Kerala Ayurveda share price has shown a year-to-date negative return of approximately 27.78 percent.

Kerala Ayurveda’s stock performance over time has closely followed India’s pharmaceutical demand and wellness industry trends. The Kerala Ayurveda share price showed positive momentum in prior years when the company expanded its wellness center network and product portfolio. However, periods of high raw material costs and competitive pressures have contributed to consolidation in the stock price. The company’s profit after tax has shown losses in recent fiscal years, reflecting the challenges in the pharmaceutical industry. The company reported a net loss of approximately 4.45 crore rupees in the December 2025 quarter, 6.34 crore rupees in the September 2025 quarter, and 15.54 crore rupees in the March 2025 quarter, with only a brief profit of 1.99 crore rupees in the June 2025 quarter. These returns highlight the cyclical and competitive nature of the pharmaceutical industry.

Despite COVID-19 disruptions, Kerala Ayurveda shares have shown responsiveness to business developments. The company has an employee count of approximately 367 people. The company has reported total revenue of approximately 72.69 crore rupees for the fiscal year ended March 2025, with other income of 5.17 crore rupees. The company has also expanded its wellness centre network and continues to operate ayurvedic academies and healthcare facilities.

Kerala Ayurveda share price has seen decreases due to several recurring reasons. A decline in demand for ayurvedic products or a drop in wellness service utilization directly impacts profitability and leads to selling pressure. Changes in government policy, such as stricter environmental regulations for pharmaceutical manufacturing or changes in AYUSH standards, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement (medicinal herbs) or energy expenses without a matching rise in product prices squeezes the company’s margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending raise concerns about wellness tourism and discretionary healthcare spending, leading to a drop in Kerala Ayurveda share price. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in capacity utilization or lower sales in any product category directly hurts the company’s revenue, resulting in a lower valuation for Kerala Ayurveda share price.

Kerala Ayurveda Limited Investor Relevance and Role in Portfolio

Kerala Ayurveda Limited is a holding in small-cap and pharmaceutical portfolios, offering exposure to ayurvedic medicines, wellness services, healthcare facilities, and ayurvedic education. Inclusion in pharmaceutical indices underscores its importance in India’s ayurvedic healthcare space. The company’s long operating history since 1945, its integrated ayurvedic healthcare model spanning products, services, and education, and its diversified revenue streams make it a consideration for long-term allocations.

Kerala Ayurveda stock price is influenced by the company’s ownership structure. Kerala Ayurveda equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable stake of approximately 33.14 percent in the company, reflecting consistent long-term commitment. A portion of promoter holdings, approximately 23.56 percent, is pledged as collateral. Foreign institutional investors hold approximately 0.22 percent of the company’s shares, showing initial levels of foreign interest. Domestic institutional investors hold approximately 0.04 percent of the company’s shares. Mutual funds hold a negligible stake of approximately 0.02 percent. Public and retail investors hold the remaining stake of approximately 66.60 percent in the company. The company’s management includes Dr. Kunjupanicker Anilkumar as Whole Time Director, Vivek Sunder as Chief Executive Officer, and K. T. George as Chief Financial Officer. This investor base with significant public participation and some institutional interest underscores the company’s role as a holding in both domestic and focused portfolios concentrating on ayurvedic pharmaceutical manufacturing and healthcare services.

Beyond fundamentals and ownership, Kerala Ayurveda stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on product demand, wellness service utilization, and regulatory policy actions affecting the pharmaceutical and healthcare sectors. The stock is available for trading on the BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements.

Technical indicators provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s beta of approximately 0.65 over one year indicates moderate volatility compared to the broader market, while the three-year beta of 0.96 suggests near-market correlation. The company’s debt-to-equity ratio stands at approximately 15.49, indicating significant financial leverage. The return on equity of negative 417.29 percent and return on capital employed of negative 15.11 percent reflect the company’s recent financial challenges and capital-intensive pharmaceutical business· The company’s book value per share stands at approximately 9.92 to 20.34 rupees.

Overall, Kerala Ayurveda demonstrates a volatile financial profile with significant leverage and negative profitability metrics, making it sensitive to broader market movements and sector-specific factors such as raw material price fluctuations, healthcare demand cycles, and regulatory changes affecting the pharmaceutical industry, while its long-term brand legacy and integrated business model provide some stability.

Kerala Ayurveda Limited Sectoral Relevance and Peer Positioning

Kerala Ayurveda Limited sector relevance stems from its eight decades of presence in the ayurvedic pharmaceutical industry, its integrated business model spanning manufacturing of classical and proprietary ayurvedic medicines, health supplements, skin and beauty care products, wellness centers, clinics, hospitals, yoga therapy services, ayurvedic academies, and medicinal plant cultivation, establishing it as a focused small-cap ayurvedic healthcare provider supporting India’s traditional medicine and wellness ecosystem. Peer comparisons with companies in the pharmaceutical and wellness sector such as Sun Pharmaceutical Industries, Divis Laboratories, Torrent Pharmaceuticals, Cipla, Dr. Reddy’s Laboratories, Lupin , and other ayurvedic and pharmaceutical manufacturers focus on product portfolio diversification, regulatory compliance, manufacturing scale, and geographic presence rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of ayurvedic medicine demand, wellness tourism trends, and regulatory compliance further highlights Kerala Ayurveda positioning within India’s broader pharmaceutical and healthcare market.

Kerala Ayurveda P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from ayurvedic medicines and healthcare services. Based on available data, the current P/E ratio stands at negative 13.16 to negative 12.56 times, indicating that the stock trades at a loss-making valuation. The company’s profit after tax has shown losses in recent fiscal years, with a net loss of approximately 13.48 crore rupees before exceptional items for the fiscal year ended March 2025. Quarterly performance has shown variation, with revenue of approximately 34.09 crore rupees in the December 2025 quarter, compared to 36.54 crore rupees in the September 2025 quarter, a sequential decline, but a year-on-year increase from 31.36 crore rupees in the December 2024 quarter. The company’s EBIT margin and net profit margin have remained negative in recent quarters, reflecting ongoing operational challenges. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical and competitive industry.

Alongside valuation, Kerala Ayurveda EPS provides insight into its operational performance and income generation from ayurvedic medicines, health supplements, beauty products, wellness services, and educational programs. Based on available data, the company reported a trailing twelve month EPS of approximately negative 18.72 rupees. The company’s EPS for the December 2025 quarter stood at negative 3.69 rupees, compared to negative 7.23 rupees in the September 2025 quarter, showing some sequential improvement, but worse than the negative 2.40 rupees in the December 2024 quarter. The company has a face value of 10 rupees per share and has not paid any dividends in recent years.

Kerala Ayurveda market cap highlights its position as a small-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization has fluctuated, standing at approximately 293.47 to 319.68 crore rupees depending on the reporting period. The company’s market cap has moved in line with investor perceptions of the company’s growth potential following significant corrections from its highs. From earlier years through more recent periods, the market cap showed an increasing trend as the company expanded its wellness centre network and diversified its product portfolio, followed by a significant correction. This pattern reflects strong investor confidence during favourable pharmaceutical cycles and wellness trends, followed by contraction during challenging periods impacted by rising raw material costs and increased competitive pressures. This decrease mirrors the correction in the Kerala Ayurveda share price from its 52-week high of approximately 625.00 to recent levels around 150.00 to 250.00 rupees per share.

Finally, Kerala Ayurveda earnings trajectory demonstrates the impact of its operational execution in a competitive and capital-intensive industry. In recent fiscal years, total income showed trends supported by the core ayurvedic pharmaceutical business. Based on available data, the company’s revenue from operations for the fiscal year ended March 2025 stood at approximately 72.69 crore rupees, slightly lower than the 73.14 crore rupees recorded in the previous fiscal year, representing a modest decline. Total income including other income of 5.17 crore rupees reached 77.86 crore rupees. Profit after tax before exceptional items stood at a loss of approximately 13.48 crore rupees, compared to a profit of 0.43 crore rupees in the previous fiscal year. Quarterly performance has shown variation, with revenue in the December 2025 quarter at approximately 34.09 crore rupees, down from 36.54 crore rupees in the September 2025 quarter, but up from 31.36 crore rupees in the December 2024 quarter. The company has faced headwinds from fluctuating raw material prices for medicinal herbs, increased competitive pressures, and regulatory compliance costs. However, the company continues to maintain its brand legacy, expand its wellness centre network, and benefit from the growing consumer awareness of ayurvedic and holistic healthcare solutions. These developments illustrate the cyclical and competitive nature of the pharmaceutical industry and the company’s position within this sector.

Summary

Kerala Ayurveda Limited operates as an ayurvedic pharmaceutical and healthcare services company offering medicines, wellness centres, clinics, hospitals, and educational programs. Kerala Ayurveda share price moves largely with pharmaceutical demand cycles, raw material costs, and broader healthcare sector conditions, while also being influenced by wellness tourism trends and consumer preferences for natural healthcare. Kerala Ayurveda stock price reflects its specific position within the small-cap ayurvedic pharmaceutical space. The company’s performance aligns with the operational results of its diversified product and service portfolio, supported by a long-standing brand legacy in ayurvedic healthcare since 1945.